What Is GILD Fair Value?
Gilead Sciences Inc. (GILD) fair value estimate using multiple valuation models, updated daily.
As of October 31, 2026, Gilead Sciences Inc. (GILD) has a composite fair value estimate of $268.25 based on four valuation models: DCF (70% weight), Graham Number (0% weight), PEG (0% weight), and DDM (30% weight). The current market price is $170.68, suggesting the stock is undervalued by 57.2%.
Data as of October 31, 2026 (today)
Composite Fair Value
Undervalued2 of 4 models$268.25
vs. current price of $170.68(+57.2%)
How Is GILD Fair Value Calculated?
Four independent models estimate what GILD is worth. Each uses different inputs and assumptions. The composite blends them by weight.
GILD Intrinsic Value
Forward-looking models based on future cash flows
DCF (Discounted Cash Flow)
70% weightEstimates how much cash the company will generate over the next 10 years, then calculates what all that future cash is worth in today's dollars. Includes a 15% safety cushion. Try the standalone DCF calculator →
$293.72
+72.1%Undervalued
Inputs used
DDM (Dividend Discount Model)
30% weightIf a company pays you dividends, this model asks: how much are all those future dividend payments worth today? Only works for stocks that pay dividends. Try the intrinsic value calculator →
$87.87
-48.5%Overvalued
Inputs used
GILD Fair Value
Current fundamentals: earnings, assets, and growth rate
Graham Number (Value Investing)
0% weightCreated by legendary investor Benjamin Graham. It looks at two things: how much the company earns (EPS) and what its assets are worth (Book Value), then calculates the maximum price a careful investor should pay. Try the fair value calculator →
N/A
Requires positive EPS and book value. Gilead Sciences Inc. currently has negative earnings, so the Graham formula cannot be applied.
Inputs used
PEG (Price/Earnings to Growth)
0% weightChecks if you're paying a fair price for the company's growth. A fast-growing company deserves a higher price than a slow one. This model finds the right price based on how fast earnings are growing.
N/A
Requires positive earnings per share. Gilead Sciences Inc. is not yet profitable, so the PEG model cannot calculate a fair price.
Inputs used
What If You Change the Assumptions?
Drag the sliders to test different scenarios. Tap the ? buttons to learn what each input means.
Your DCF Fair Value
Current price $170.68 is 72.1% below this estimate
View 10-year cash flow projections
| Year | Projected FCF (Free Cash Flow) | Present Value |
|---|---|---|
| Year 1 | $13.27B | $12.52B |
| Year 2 | $13.94B | $12.39B |
| Year 3 | $14.64B | $12.27B |
| Year 4 | $15.37B | $12.14B |
| Year 5 | $16.14B | $12.02B |
| Year 6 | $16.94B | $11.90B |
| Year 7 | $17.79B | $11.78B |
| Year 8 | $18.68B | $11.66B |
| Year 9 | $19.61B | $11.55B |
| Year 10 | $20.59B | $11.43B |
| Terminal Value | $592.57B | $328.96B |
What Are GILD's Key Financial Metrics?
Earnings & Growth
Current Price
$170.68
EPS (TTM)
-$3.13
Forward P/E
16.9
Profit Margin
-12.5%
Cash & Balance Sheet
Free Cash Flow
12.6B
EBITDA
15.4B
Book Value
$10.44
Total Debt
26.5B
What Do Analysts Say About GILD?
Low
$131.00
Average
$170.88
High
$200.00
Upside
+0.1%
GILD Fair Value FAQ
What is the fair value of GILD?
Based on our composite model (DCF 35%, Graham 25%, PEG 25%, DDM 15%), GILD's estimated fair value is $268.25. The stock is currently trading at $170.68, which makes it undervalued by our analysis.
How is GILD's fair value calculated?
We use four valuation methods: Discounted Cash Flow (DCF), Graham Number, PEG-based Fair Value, and Dividend Discount Model (for dividend-paying stocks). The composite score weights DCF at 35%, Graham and PEG at 25% each, and DDM at 15%. When a model can't be applied, its weight is redistributed proportionally.
Is GILD overvalued or undervalued?
Based on our analysis, GILD is undervalued. The current price of $170.68 is 57.2% below our estimated fair value of $268.25.
What do Wall Street analysts say about GILD?
26 analysts cover Gilead Sciences Inc. with a consensus rating of "Buy." The average price target is $170.88, ranging from $131.00 to $200.00. This implies 0.1% upside from the current price.